Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Earns Equal Weighted Rating from Morgan Stanley Analysts

0

Morgan Stanley analysts have started covering shares of Fresenius Medical Care AG & Co. KGaA (New York Stock Exchange: FMSGet a rating) in a note released Tuesday to investors, Fly reports. The company has set an “equal weight” rating on the stock.

Other equity research analysts have also recently published research reports on the stock. DZ Bank reduced shares of Fresenius Medical Care AG & Co. KGaA from a “buy” rating to a “hold” rating in a Friday, July 29 report. Berenberg Bank lowered its price target on shares of Fresenius Medical Care AG & Co. KGaA from €76.70 ($78.27) to €57.95 ($59.13) in a Wednesday, August 10 report. Truist Financial cut its price target on shares of Fresenius Medical Care AG & Co. KGaA from $34.00 to $27.00 and set a “hold” rating for the company in a Wednesday 22 research report June. UBS Group downgraded shares of Fresenius Medical Care AG & Co. KGaA from a “buy” rating to a “neutral” rating in a Friday, July 29 research report. Finally, Jefferies Financial Group downgraded shares of Fresenius Medical Care AG & Co. KGaA from a “buy” rating to a “hold” rating in a Monday, October 10 research report. One equity research analyst assigned the stock a sell rating, nine assigned a hold rating and three assigned the company’s stock a buy rating. Based on MarketBeat data, Fresenius Medical Care AG & Co. KGaA currently has a consensus rating of “Hold” and an average price target of $45.83.

Fresenius Medical Care AG & Co. KGaA share performance

Shares of FMS opened at $13.56 on Tuesday. The company has a market capitalization of $7.95 billion, a PE ratio of 8.64, a P/E/G ratio of 0.73 and a beta of 1.06. The company has a debt ratio of 0.47, a current ratio of 1.18 and a quick ratio of 0.85. Fresenius Medical Care AG & Co. KGaA has a one-year low of $12.78 and a one-year high of $36.08. The stock has a 50-day moving average of $16.12 and a 200-day moving average of $23.55.

Fresenius Medical Care AG & Co. KGaA (New York Stock Exchange: FMSGet a rating) last announced its results on Thursday, July 28. The company reported earnings per share of $0.41 for the quarter, missing analyst consensus estimates of $0.45 per ($0.04). Fresenius Medical Care AG & Co. KGaA achieved a return on equity of 6.70% and a net margin of 4.42%. The company posted revenue of $5.07 billion in the quarter, compared to $4.80 billion expected by analysts. On average, equity research analysts expect Fresenius Medical Care AG & Co. KGaA to post 1.5 EPS for the current fiscal year.

Hedge funds weigh on Fresenius Medical Care AG & Co. KGaA

Several hedge funds and other institutional investors have recently changed their FMS holdings. Legacy Wealth Asset Management LLC increased its stake in shares of Fresenius Medical Care AG & Co. KGaA by 18.3% during the third quarter. Legacy Wealth Asset Management LLC now owns 63,714 shares of the company valued at $895,000 after purchasing an additional 9,856 shares last quarter. National Bank of Canada FI increased its holdings of Fresenius Medical Care AG & Co. KGaA shares by 6.0% during the third quarter. National Bank of Canada FI now owns 17,737 shares of the company valued at $244,000 after purchasing an additional 1,006 shares in the last quarter. Cacti Asset Management LLC increased its holdings of Fresenius Medical Care AG & Co. KGaA shares by 20.8% during the third quarter. Cacti Asset Management LLC now owns 43,500 shares of the company valued at $611,000 after purchasing an additional 7,500 shares in the last quarter. State Street Corp increased its holdings of shares of Fresenius Medical Care AG & Co. KGaA by 102.4% during the second quarter. State Street Corp now owns 20,954 shares of the company valued at $523,000 after buying an additional 10,600 shares in the last quarter. Finally, Cubist Systematic Strategies LLC increased its equity stake in Fresenius Medical Care AG & Co. KGaA by 202.6% during the second quarter. Cubist Systematic Strategies LLC now owns 91,369 shares of the company valued at $2,279,000 after purchasing an additional 61,179 shares last quarter. 5.59% of the shares are held by institutional investors.

About Fresenius Medical Care AG & Co. KGaA

(Get a rating)

Fresenius Medical Care AG & Co KGaA provides dialysis care and related dialysis care services in Germany, North America and abroad. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; equipment, training and patient support services including clinical monitoring, assisting with follow-up and arranging delivery of supplies to the patient’s home; and contracted dialysis services with hospitals in the United States for hospitalized patients with end-stage renal disease (ESRD) and for patients with acute renal failure.

Read more

The Fly logo

Analyst Recommendations for Fresenius Medical Care AG & Co. KGaA (NYSE: FMS)

This instant news alert was powered by MarketBeat’s storytelling science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]

Before you consider Fresenius Medical Care AG & Co. KGaA, you’ll want to hear this.

MarketBeat tracks daily the highest rated and most successful research analysts on Wall Street and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market spreads… and Fresenius Medical Care AG & Co. KGaA was not on the list.

While Fresenius Medical Care AG & Co. KGaA currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better buys.

See the five actions here

Share.

Comments are closed.